Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 17/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.57 |
| ▸ | CDK4 | P11802 | 4/20 | 0.52 |
| ▸ | CDK1 | P06493 | 3/20 | 0.52 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.52 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.52 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.52 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.52 |
| ▸ | CCND1 | P24385 | 1/20 | 0.52 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.52 |
| ▸ | CCND3 | P30281 | 1/20 | 0.52 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.52 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.52 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.52 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.52 |
| ▸ | GSK3A | P49840 | 1/20 | 0.52 |
| ▸ | GSK3B | P49841 | 1/20 | 0.52 |
| ▸ | CDK7 | P50613 | 1/20 | 0.52 |
| ▸ | CDK9 | P50750 | 1/20 | 0.52 |
| ▸ | CCNH | P51946 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL4253108 | 0.93 | CDK2 (0.57) | CDK2KCNH2CDK4CDK1CCNT1 | |
| SCHEMBL278830 | 0.85 | CDK2 (0.56) | CDK2KCNH2CDK4CDK1CCNT1 | |
| SCHEMBL3207123 | 0.82 | CDK2 (0.60) | CDK2KCNH2CDK4CDK1CCNT1 | |
| SCHEMBL4253102 | 0.77 | CDK2 (0.53) | CDK2KCNH2CDK4CDK1CCNT1 | |
| SCHEMBL4505142 | 0.75 | CDK2 (0.49) | CDK2KCNH2CDK4CDK1CCNT1 | |
| SCHEMBL5098885 | 0.74 | CDK2 (0.78) | CDK2KCNH2CDK4CDK1CCNT1 | |
| SCHEMBL4510605 | 0.74 | CDK2 (1.00) | CDK2KCNH2CDK4CDK1CCNT1 | |
| SCHEMBL4505095 | 0.73 | CDK2 (0.74) | CDK2KCNH2CDK4CDK1CCNT1 | |
| SCHEMBL278928 | 0.72 | CDK2 (0.82) | CDK2KCNH2CDK4CDK1CCNT1 | |
| SCHEMBL1447341 | 0.71 | CDK2 (0.81) | CDK2KCNH2CDK4CDK1CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4572755-A2 | CDK2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-06-25 | — | — | EP | disclosed |
| EP-4573094-A2 | CDK2 INHIBITORS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-06-25 | — | — | EP | disclosed |
| CN-117715904-A | CDK2 degrading agents and uses thereof | 凯麦拉医疗公司 | 2024-03-15 | — | — | CN | disclosed |
| EP-4334307-A1 | CDK2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| WO-2024039903-A2 | CDK2 INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2024-02-22 | — | — | WO | disclosed |
| WO-2024039903-A2 | CDK2 INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2024-02-22 | — | — | WO | disclosed |
| WO-2024039901-A2 | CDK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2024-02-22 | — | — | WO | disclosed |
| US-20230110180-A1 | CDK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-13 | — | — | US | disclosed |
| WO-2022236058-A1 | CDK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2022-11-10 | — | — | WO | disclosed |
| US-20100063049-A1 | 2-CARBOCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHBITION OF CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2010-03-11 | — | — | US | disclosed |
| US-20090275567-A1 | 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
| EP-2032559-A1 | 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | AstraZeneca AB (SE) | 2009-03-11 | — | — | EP | disclosed |
| EP-2029578-A1 | 2-CARBOCYCLOAMINO-4-IMIDAZ0LYLPYRIMIDINES AS AGENTS FOR THE INHBITION OF CELL PROLIFERATION | AstraZeneca AB (SE) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007138268-A1 | 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007138277-A1 | 2-CARBOCYCLOAMINO-4-IMIDAZ0LYLPYRIMIDINES AS AGENTS FOR THE INHBITION OF CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063049-A1 | 2-CARBOCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHBITION OF CELL PROLIFERATION | MKI67, CCNI, CDK2 | CDK2 3/4885KCNH2 2260/4885CDK4 19/4885 |
| US-20230110180-A1 | CDK2 DEGRADERS AND USES THEREOF | CDK2, CDK20, CDK1 | CDK2 1/4885KCNH2 4836/4885CDK4 4/4885 |
| US-20090275567-A1 | 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | CCNI, MKI67, CDK2 | CDK2 3/4885KCNH2 3454/4885CDK4 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.